IL142980A0 - Nucleic acid constructs for genetic immunization - Google Patents

Nucleic acid constructs for genetic immunization

Info

Publication number
IL142980A0
IL142980A0 IL14298099A IL14298099A IL142980A0 IL 142980 A0 IL142980 A0 IL 142980A0 IL 14298099 A IL14298099 A IL 14298099A IL 14298099 A IL14298099 A IL 14298099A IL 142980 A0 IL142980 A0 IL 142980A0
Authority
IL
Israel
Prior art keywords
nucleic acid
acid constructs
molecules
genetic immunization
sequence encoding
Prior art date
Application number
IL14298099A
Other languages
English (en)
Original Assignee
Powderject Vaccines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Powderject Vaccines Inc filed Critical Powderject Vaccines Inc
Publication of IL142980A0 publication Critical patent/IL142980A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • C12N9/6459—Plasminogen activators t-plasminogen activator (3.4.21.68), i.e. tPA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IL14298099A 1998-11-05 1999-11-05 Nucleic acid constructs for genetic immunization IL142980A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10716998P 1998-11-05 1998-11-05
PCT/US1999/026291 WO2000026385A1 (en) 1998-11-05 1999-11-05 Nucleic acid constructs for genetic immunization

Publications (1)

Publication Number Publication Date
IL142980A0 true IL142980A0 (en) 2002-04-21

Family

ID=22315199

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14298099A IL142980A0 (en) 1998-11-05 1999-11-05 Nucleic acid constructs for genetic immunization

Country Status (13)

Country Link
EP (1) EP1119630B1 (https=)
JP (1) JP2002528123A (https=)
AT (1) ATE315658T1 (https=)
AU (1) AU775939B2 (https=)
CA (1) CA2349505A1 (https=)
CY (1) CY1105600T1 (https=)
DE (1) DE69929470T2 (https=)
DK (1) DK1119630T3 (https=)
ES (1) ES2257879T3 (https=)
IL (1) IL142980A0 (https=)
NZ (1) NZ512078A (https=)
PT (1) PT1119630E (https=)
WO (1) WO2000026385A1 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6933366B2 (en) 1996-12-27 2005-08-23 Tripep Ab Specificity exchangers that redirect antibodies to bacterial adhesion receptors
US6660842B1 (en) 1994-04-28 2003-12-09 Tripep Ab Ligand/receptor specificity exchangers that redirect antibodies to receptors on a pathogen
US6802826B1 (en) 1999-10-11 2004-10-12 Felton International, Inc. Universal anti-infectious protector for needleless injectors
US7887506B1 (en) 1999-11-23 2011-02-15 Pulse Needlefree Systems, Inc. Safety mechanism to prevent accidental patient injection and methods of same
ATE320493T1 (de) * 2000-06-22 2006-04-15 Ucb Pharma Ltd Modifizierung des hepatitis b kernantigens
CA2421877A1 (en) * 2000-09-19 2002-03-28 Tripep Ab Ligand/receptor specificity exchangers that redirect antibodies to receptors on a pathogen
JP2004535799A (ja) * 2001-05-18 2004-12-02 パウダージェクト ワクチンズ，インコーポレーテッド ワクチン組成物
DE10143490C2 (de) * 2001-09-05 2003-12-11 Gsf Forschungszentrum Umwelt Rekombinantes MVA mit der Fähigkeit zur Expression von HCV Struktur-Antigenen
EP1545593A1 (en) * 2002-09-27 2005-06-29 PowderJect Research Limited Nucleic acid coated particles
US7335359B2 (en) 2003-02-06 2008-02-26 Tripep Ab Glycosylated specificity exchangers
EP1594898A2 (en) 2003-02-06 2005-11-16 Tripep AB Glycosylated specificity exchangers
JP2010505883A (ja) 2006-10-12 2010-02-25 ザ ユニバーシティー オブ クイーンズランド 免疫応答を調節するための組成物および方法
KR101413844B1 (ko) 2008-12-09 2014-06-30 화이자 백신스 엘엘씨 ＩｇＥ ＣＨ３ 펩티드 백신
NZ598356A (en) 2009-07-30 2014-06-27 Pfizer Vaccines Llc Antigenic tau peptides and uses thereof
PE20161551A1 (es) 2009-09-03 2017-01-18 Pfizer Vaccines Llc Vacuna de pcsk9
EP2575868A1 (en) 2010-06-07 2013-04-10 Pfizer Vaccines LLC Ige ch3 peptide vaccine
BR112013010926A2 (pt) 2010-11-01 2016-08-23 Univ Technology Sidney agentes imunomoduladores e seus usos
CN103442732B (zh) 2011-02-11 2017-04-12 宾夕法尼亚大学托管会 编码乙型肝炎病毒核心蛋白的核酸分子和包含其的疫苗
US20140004142A1 (en) 2011-03-02 2014-01-02 Pfizer Inc. Pcsk9 vaccine

Also Published As

Publication number Publication date
ATE315658T1 (de) 2006-02-15
DE69929470D1 (de) 2006-04-06
WO2000026385A1 (en) 2000-05-11
NZ512078A (en) 2004-01-30
DK1119630T3 (da) 2006-05-15
JP2002528123A (ja) 2002-09-03
AU2022200A (en) 2000-05-22
ES2257879T3 (es) 2006-08-01
WO2000026385A9 (en) 2000-10-26
CA2349505A1 (en) 2000-05-11
EP1119630A1 (en) 2001-08-01
AU775939B2 (en) 2004-08-19
DE69929470T2 (de) 2006-08-24
CY1105600T1 (el) 2010-07-28
EP1119630B1 (en) 2006-01-11
PT1119630E (pt) 2006-05-31

Similar Documents

Publication Publication Date Title
IL142980A0 (en) Nucleic acid constructs for genetic immunization
EP0460076A4 (en) Genetically engineered immunoglobulins
IL188875A0 (en) Tumor-associated antigen derivatives from the mage family, and nucleic acid sequences encoding them, used for the preparation of fusion proteins and of compositions for vaccination
WO1999058658A3 (en) Expression vectors for stimulating an immune response and methods of using the same
NZ503763A (en) Antigenic compositions and vaccines comprising a high molecular weight (HMW) protein of Clamydia for therapeutic and prophylactic use
WO2001073059A3 (en) 38692 and 21117: dual specificity phosphatase molecules and uses therefor
AU1800597A (en) Novel methods of vaccination and vaccines therefore comprising a nucleic acid encoding a first epitope and a peptide containing a second epitope
WO2000075358A3 (en) Mammalian toll homologues and uses thereof
WO2000063385A3 (en) Nucleic acid immunization
WO2002103015A3 (en) Abca10 transporter
WO2002002760A3 (en) 25869, a human carboxylesterase and uses thereof
DE69533504D1 (de) Monoklonale antikörper gegen antigene, die durch hämatopoietische helferzellen exprimiert werden
MXPA03010527A (es) Composicion de vacuna.
DK0691404T3 (da) Vaccine til immunisering mod TBE-virusinfektioner samt en fremgangsmåde til fremstilling deraf
WO2001094390A3 (en) 52906, 33408, and 12189, potassium channel family members and uses thereof
WO2000047227A3 (en) Mycobacterium tuberculosis, immunization
WO2002026803A3 (en) 22108 and 47916, novel human thioredoxin family members and uses thereof
WO2001064904A3 (en) 25324, 50287, 28899, 47007, and 42967 transferase family members and uses therefor
WO2002070691A3 (en) Abcg4 transporter and uses thereof
DK1328621T3 (da) 13245, en ny human proteinkinase af den myotoniske dystrofitype og anvendelser deraf
AU2001285204A1 (en) Atcr-1, a human acyltransferase and uses thereof
MXPA01011563A (es) Una novedosa proteina 5 relacionada al factro-h y anticuerpos relacionados.
WO2002095032A3 (en) Methods and compositions of human proteins and uses thereof.
WO2002002761A3 (en) 57658, a human uridine kinase and uses thereof
WO2001096548A3 (en) Human n-acetyltransferase family member and uses thereof